SCHEMBL1033282

SCHEMBL1033282

Cc1ccc2[nH]c(=O)c(C(=O)O)c(O)c2c1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 2/20 0.43
GRIN3B O60391 2/20 0.43
GRIN1 Q05586 2/20 0.43
GRIN2A Q12879 2/20 0.43
GRIN2B Q13224 2/20 0.43
GRIN2C Q14957 2/20 0.43
GRIN3A Q8TCU5 2/20 0.43
CDK1 P06493 1/20 0.43
CDK2 P24941 1/20 0.43
KDM4E B2RXH2 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
DPP4 P27487 1/20 0.39
GRIK1 P39086 1/20 0.38
GRIA1 P42261 1/20 0.38
GRIA2 P42262 1/20 0.38
GRIA3 P42263 1/20 0.38
GRIA4 P48058 1/20 0.38
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL321280 0.85 USP2 (0.44) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL1033018 0.82 KDM5A (0.53) KDM4ETDP1MEN1POLBMAPT
SCHEMBL322013 0.82 CA12 (0.41) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL7818937 0.81 PTGS2 (0.44) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL2483507 0.80 KDM4E (0.50) KDM4ETDP1KMT2A
SCHEMBL7826753 0.80 KDM4E (0.38) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL321442 0.79 MEN1 (0.45) TDP1MEN1POLBMAPTKMT2A
SCHEMBL7861633 0.79 KDM4E (0.37) CDK1CDK2KDM4ETDP1GRIK1
SCHEMBL7557817 0.79 GPBAR1 (0.40) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL7558468 0.79 GPBAR1 (0.38) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376456-A2 HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Actavis Group Ptc Ehf (IS) 2011-10-19 EP claimed
EP-2276740-A1 IMPROVED PROCESS FOR PREPARING QUINOLINE-3-CARBOXAMIDE DERIVATIVES Actavis Group PTC EHF (IS) 2011-01-26 EP claimed
WO-2010070449-A2 HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ACTAVIS GROUP PTC EHF (IS) 2010-06-24 WO claimed
WO-2009133468-A1 IMPROVED PROCESS FOR PREPARING QUINOLINE-3-CARBOXAMIDE DERIVATIVES ACTAVIS GROUP PTC EHF (IS) 2009-11-05 WO claimed
EP-2642855-A1 INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF QUINOLINE DERIVATIVES SUCH AS LAQUINIMOD SODIUM Mapi Pharma Limited (IL) 2013-10-02 EP disclosed
WO-2012070051-A1 INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF QUINOLINE DERIVATIVES SUCH AS LAQUINIMOD SODIUM MAPI PHARMA LTD. (IL) 2012-05-31 WO disclosed
EP-2376456-A2 HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Actavis Group Ptc Ehf (IS) 2011-10-19 EP disclosed
EP-2318371-A2 NOVEL SOLID STATE FORMS OF LAQUINIMOD AND ITS SODIUM SALT Actavis Group PTC EHF (IS) 2011-05-11 EP disclosed
EP-2276740-A1 IMPROVED PROCESS FOR PREPARING QUINOLINE-3-CARBOXAMIDE DERIVATIVES Actavis Group PTC EHF (IS) 2011-01-26 EP disclosed
WO-2010070449-A2 HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ACTAVIS GROUP PTC EHF (IS) 2010-06-24 WO disclosed
WO-2010001257-A2 NOVEL SOLID STATE FORMS OF LAQUINIMOD AND ITS SODIUM SALT ACTAVIS GROUP PTC EHF (IS) 2010-01-07 WO disclosed
WO-2009133468-A1 IMPROVED PROCESS FOR PREPARING QUINOLINE-3-CARBOXAMIDE DERIVATIVES ACTAVIS GROUP PTC EHF (IS) 2009-11-05 WO disclosed
EP-1224172-A1 DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS Active Biotech AB (SE) 2002-07-24 EP disclosed
WO-2001030758-A1 DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS ACTIVE BIOTECH AB (SE) 2001-05-03 WO disclosed